Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

St. Jude v. Guidant

This article was originally published in The Gray Sheet

Executive Summary

Proceedings begin Aug. 10 to review claims that Guidant Cardiac Pacemakers Inc.' s Vigor pacemakers and Ventak Mini implantable cardioverter defibrillators infringe U.S. patents held by St. Jude's Pacesetter division, St. Jude reports May 8. Filed May 3, 1996, the suit seeks an order permanently enjoining CPI from infringing three separate patents, as well as damages, pre and post-judgment interest and costs ("The Gray Sheet" May 13, 1996, I&W-7). St. Jude also makes public a May 4 federal appeals court decision reversing a February 1997 federal district court ruling that had denied a St. Jude request to arbitrate a dispute with Guidant regarding St. Jude's $115 mil. acquisition of Telectronics Group. Guidant asserts that the deal violates its contractual and licensing rights

You may also be interested in...



HHS Policy Move Means FDA Must Publish More Documentation To Support Rulemaking Decisions

To be more transparent and allow more public discourse, the HHS now requires all its agencies to publish documents it uses to rationalize proposed rules and demonstration projects.

Dr Reddy's Strengthens Russian OTC Portfolio Through Glenmark Deal

Dr Reddy's is poised to expand its OTC offering in Russia and certain CIS countries by snapping up a basket of allergy brands from India's Glenmark.

Moderna Files COVID-19 Vaccine After Second Impressive Read-Out

Second read-out maintains 94% level of efficacy, with a very early signal that it could outperform Pfizer’s rival mRNA candidate in preventing severe cases.

UsernamePublicRestriction

Register

LL010986

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel